1 March 2021 - The March 2021 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The March issue of the Schedule includes a few new/revised listings:

• Amino acid formula with vitamins and minerals without methionine (HCU Lophlex) - new formulation
• Amino acid formula with vitamins and minerals without phenylalanine and tyrosine (TYR Lophlex) - new formulation
• Amino acid formula with vitamins and minerals without valine, leucine and isoleucine (MSUD Lophlex) - new formulation
• Dulaglutide (Trulicity) - new indication
• Dupilumab (Dupixent) - new medicine
• Mometasone furoate with indacaterol maleate (Atectura Breezhaler) - new combination product
• Ozanimod hydrochloride (Zeposia) - new medicine
• Tiotropium bromide monohydrate (Spiriva Respimat) - new formulation
  
• Tiotropium bromide monohydrate with olodaterol hydrochloride (Spiolto Respimat) - new formulation
  

Read Summary of Changes